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They argued that one of the merits of the study
by Shah et al. (1) was the high prevalence of
warfarin users and that one of the merits of our
study was that we were able to distinguish between
patients on hemodialysis and patients on peritoneal
dialysis. Unfortunately, consensus on this important
subject has not yet been reached, and the prevalence
of warfarin usage among patients with AF and severe
chronic kidney disease varies among countries and
among clinics. In a recent Swedish study of patients
with post–myocardial infarction AF (2), only 66 of
478 patients (13.8%) with an estimated glomerular
ﬁltration rate of <16 ml/min/1.73 m2 received
warfarin at baseline compared with 46.0% of dialysis
patients in the study by Shah et al. (1).We agree that the net clinical beneﬁt of warfarin
may be different in patients with AF on peritoneal
dialysis than patients with AF on hemodialysis.
Most of the observational studies in this area have
focused on warfarin for hemodialysis patients (3,4),
and in our study, we only found a signiﬁcant effect
difference of warfarin between peritoneal and
hemodialysis patients among patients with low-risk
AF (a relatively small group) (5). Because we still
do not have data from randomized clinical trials
on the beneﬁt of warfarin in patients with AF on
dialysis, new data from observational cohorts are
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